CDKN2A and acute lymphoblastic leukemia: However, other genetic defects leading to TP53 mRNA downregulation [33] or p53 protein degradation, such as a mouse double minute 2 homolog (MDM2) overexpression or cyclin-dependent kinase inhibitor 2A (CDKN2A) deletion, are more frequently found in BCP-ALL [34].